Browning DD. Type 2 cGMP-dependent protein kinase regulates proliferation and differentiation in the colonic mucosa.
mice using histological markers of proliferation and differentiation. The effect of ectopic PKG2 on proliferation and differentiation was tested in vitro using inducible colon cancer cell lines. PCR and luciferase reporter assays were used to determine the importance of Sox9 downstream of PKG2. The colons of Prkg2 Ϫ/Ϫ mice exhibited crypt hyperplasia, increased epithelial apoptosis, and reduced numbers of differentiated goblet and enteroendocrine cells. Ectopic PKG2 was able to inhibit proliferation and induce Muc2 and CDX2 expression in colon cancer cells, but did not significantly affect cell death. PKG2 reduced Sox9 levels and signaling, suggesting possible involvement of this pathway downstream of cGMP in the colon. The work presented here demonstrates a novel antiproliferative and prodifferentiation role for PKG2 in the colon. These homeostatic functions of PKG2 were reproducible in colon cancer cells lines where downregulation of Sox9 is a possible mechanism. The similarities in phenotype between PKG2 and GCC knockout mice positions PKG2 as a likely mediator of the homeostatic effects of cGMP signaling in the colon. cGMP; Prkg2; Muc2; Sox9 CONTINUOUS RENEWAL OF THE luminal epithelium is essential for maintaining a healthy intestine, including both small intestine and colon, and disruption of this process is thought to be a major cause of gastrointestinal disease. The balance between cellular proliferation at the crypt base and terminal differentiation at the luminal surface is referred to as intestinal homeostasis and is highly regulated (39) . Numerous signaling pathways have been identified as important organizers of the crypt-surface axis. One of the most widely studied is Wnt signaling through ␤-catenin/T-cell factor (TCF), which has a critical role in the maintenance of stem cells at the crypt base (41) . The stem cells give rise to proliferative progenitor cells that undergo cell fate decisions in the transit amplifying region of the crypt. The commitment of these cells to either secretory (goblet and enteroendocrine cells) or enterocyte lineage is controlled in part by notch and bone morphogenetic protein pathways (29) . While the details are not fully understood, it is clear that complex interactions between many pathways contribute to the cessation of proliferation and induction of terminal differentiation in the intestinal mucosa.
Uroguanylin and guanylin are endogenous peptide hormones that regulate solute and water balance in the intestine (8) . These ligands bind to guanylyl cyclase C receptors (GCC) expressed on the surface of intestinal epithelial cells (IEC) and trigger intracellular cGMP production (42) . Effectors for cGMP include phosphodiesterases, ion channels, and cGMPdependent protein kinases (PKG) (27) . Two genes encode PKG in mammals (11, 12) . Type 1 PKG is widely distributed but is best characterized as a regulator of smooth muscle relaxation (25) . Type 2 PKG is more tissue restricted, but in IEC it promotes Cl Ϫ secretion and inhibits electroneutral NaCl absorption in response to guanylin/uroguanylin by regulating Na ϩ /H ϩ exchanger, Cl Ϫ /HCO 3 Ϫ exchanger, and the cystic fibrosis transmembrane conductance regulator (28, 32) . In addition to controlling electrolyte balance, the guanylin/GCC/ cGMP pathway has emerged as an important regulator of intestinal homeostasis. Guanylin knockout mice exhibit reduced cGMP levels in the colonic mucosa and have an increased proliferative compartment (44) . GCC knockout animals have a similar phenotype with hyperplastic crypts and reduced differentiation of secretory lineage cells (20) . The suppressive effect of cGMP signaling on proliferation in the colon has highlighted the potential therapeutic value of this pathway for intestinal malignancies (21) (22) (23) 40) .
Despite the significance of cGMP signaling in intestinal homeostasis, there is a paucity of established downstream signaling mechanisms. In vitro studies have identified several pathways that potentially mediate the antiproliferative effects of cGMP, including calcium entry through cyclic nucleotide gated channels (16, 35) , inhibition of ERK (37), ␤-catenin/TCF (19) , and more recently, AKT (24) . However, there are significant gaps in knowledge of the immediate signaling events, and comparatively very little known about cGMP signaling mechanisms in vivo. As an established cGMP effector in IEC, the present study has tested the role of PKG2 in intestinal homeostasis.
MATERIALS AND METHODS

Animals. The type 2 PKG knockout mouse (Prkg2
Ϫ/Ϫ
) was created in a 129S1/Sv * 129X1/SvJ genetic background (32) , and was provided by Dr. Franz Hofmann (Technische Universität München, München, Germany). A colony was maintained in the Georgia Health Sciences University, Augusta, Georgia (GHSU) Laboratory Animal Services using approved operating procedures. Genotyping PCR was performed using 1 l genomic DNA (purified by Gentra Puregene Mouse Tail kit, QIAGEN, Valencia, CA) with a common forward primer: 5=-AAGATAGTC-CTATCAAATCATGGAACG-3= (upstream of neomycin insert at the end of the first exon), a reverse primer to detect knockout: 5=-CATAGCGTTGGCTACCCGTGATATTGC-3= (within the neomycin insert) and a reverse for wild-type: 5=-GCCGCTACAGGACAGATAA-GAGACGAA-3= (intron sequence downstream of the neomycin insert). The Prkg2 Ϫ/Ϫ animals and their wild-type siblings used in all experiments were created by mating heterozygotes.
Immunohistochemistry and immunofluorescence. Cells on coverslips were fixed with 3.7% formaldehyde. Hemotoxylin and eosin, and Alcian blue/periodic acid-Schiff (AB/PAS) staining was done with standard procedures in the GHSU core histology facility. The 4=,6-diamidino-2-phenylindole (DAPI nuclear stain) was from Calbiochem (San Diego, CA). Alexa Fluor 568 secondary antibodies (Invitrogen, Carlsbad, CA) were used and VectorMount AQ mounting medium to fix slides. The 5-bromo-2=-deoxyuridine (BrdU; Invitrogen, Carlsbad, CA) was injected intraperitoneally with 1 ml/100 g body wt 2 h before death. Animal tissues were fixed with 10% formaldehyde, imbedded in paraffin, and sectioned by the histology core facility at GHSU. Antigens were unmasked in sections by heating at 100°C for 30 min in 10 mM sodium-citrate (with 0.05% Tween 20, pH ϭ 6). Antibody to lysozyme and Ki-67 (1:50 dilution; Dako Cytomation, Carpinteria, CA), BrdU (biotinated, 1:100 dilution; Abcam, Cambridge, MA), MUC2 (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), and chromogranin A (1:200 dilution; Immunostar, Hudson, WI) were purchased from commercial sources. Alkaline phosphatase was stained with the Alkaline Phosphatase kit I (catalog no. SK-5100; Vector, Burlingame, CA). Analysis was done independently by two individuals who were blinded to the mouse genotypes, and three mice of each genotype were analyzed.
Tissue culture and reagents. All cell lines were obtained from the American Type Culture Collection (ATCC, Manasses, VA) and maintained in 5% CO 2 in RMPI-1640 medium containing 10% FBS, and supplemented with 2 mM L-glutamine, 10 IU/ml penicillin, and 10 mg/ml streptomycin. Cell lines made inducible for type 2 PKG expression in response to doxycycline (Doxy) were generated using the Lenti-X lentiviral inducible expression system from Clonetech (Mountain View, CA). The medium used to maintain stocks of inducible cells was supplemented with 200 g/ml of G418 and 0.2 g/ml of puromycin. Before experimentation, the cells were grown for at least one passage in the absence of antibiotics. The Doxy, DAPI, and 8Br-cGMP were from Calbiochem. NP-40, tween-20, and puromycin were from Sigma (St. Louis, MO). G418 was from Hyclone (Logan, UT), and all other chemicals were from Fisher Scientific (Pittsburgh, PA).
Western blot analysis. Cells were lysed by incubation in ice-cold lysis buffer (50 mM HEPES pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.25% deoxycholate) supplemented with protease inhibitor cocktail (Calbiochem). Lysates were subjected to immunoblot analysis using antibodies to the following antigens: PKG2 (1:200 dilution; Santa Cruz Biotechnology), Sox9 (1:200 dilution; Abcam, Cambridge, MA), Flag (1:1,000), and ␤-actin (1:2,000) antibodies from Sigma.
Analysis of gene expression. Steady-state RNA levels were measured by semiquantitative RT-PCR. The cDNA was generated using GeneAmp PCR kits (Applied Biosystems, Foster City, CA). Gene-specific primers were designed using the National Center for Biotechnology Information Primer Blast Software as follows: human PKG2 (forward: 5=-AGCCCGCTTCAGGCCTCT CC-3=, reverse: 5=-AGTCGACCCTCT-GCCAGCAC-3=), human Sox9 (forward: 5=-GATCTGAAGAAGGA GAGCGAGGAGGACAAG-3=, reverse: 5=-CGTTGGGGGAGATGT-GCGTCTGCTC-3=), human MUC2 (forward: 5=-CCGCTGGAGCCG-TATCTGCG-3=, reverse: 5=-CGGGGCAGGGCAGGTCTTTG-3=), human CDX2 (forward: 5=-AGGCAGAAGAGCCGCGAGGA-3=, reverse: 5=-CCAGTCCTCCCGGAGTGGG G-3=), mouse PKG2 (forward: 5=-GTGGCGGAGGACGCCAAGAC-3=, reverse: 5=-AGGCCTG-CAGTGG GCTTCCT-3=), and common hypoxanthine phosphoribosyltransferase 1 (HPRT1) (forward: 5=-GCGTCGTGATTAGCGATGAT-GAAC-3=, reverse: 5=-CCTCCCATCTCCTTCATGACATCT-3=). Luciferase reporter assays were performed as described previously (19) . The Flag-Sox9, MUC2-, and CDX2-luciferase reporter constructs were described previously (2) .
Cell viability determination. For colony formation assays, the cells were seeded in six-well plates at a density of 5,000 cells/well in the presence or absence of PKG2 inducer Doxy (2 g/ml) and 8Br-cGMP (100 M). Media with fresh Doxy/8Br-cGMP was changed every other day, and colonies formed after 14 days were fixed in 100% methanol for 30 min and stained with KaryoMax Gimsa stain (Sigma) for 1 h. Stained dishes were scanned at high resolution and the total colony area for each well was determined using Scion Image software (Scion, Frederick, MD). For direct cell counts, the cells were seeded in six-well dishes with 400,000 cells/well and in the presence or absence of Doxy/8Br-cGMP for 72 h. Cells were detached and resuspended in PBS containing 0.2% trypan blue, and after 5 min the number of living (unstained) and dead (stained with blue) cells in each well were counted in a hemocytometer. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye (MTT) cell proliferation assays were also used to measure cell growth. For these studies, the cells were cultured in 96-well plates (5,000 cells/well) in the presence or absence of Doxy/8Br-cGMP, and after 48 h the reduction of MTT was determined according to the manufacturer's instructions (ATCC).
Cells were seeded in 12-well plates at 50% confluence and either untreated or treated with 2 g/ml Doxy and 100 M 8Br-cGMP. At 48 h later, cells were washed twice in cold 1ϫ PBS, harvested using trypsin-EDTA solution, and cell death was assessed using annexin-V FITC and propidium iodide double staining according to the manufacturer instructions (Annexin-V FITC Apoptosis Kit; BD Bioscience).
For cell-cycle analysis, the cells were harvested using trypsin, washed with ice-cold PBST (1ϫ PBS with 1 mM EDTA, 0.1% Triton X-100 and 1% BSA, pH ϭ 8) and then fixed for 30 min with ice-cold 70% ethanol. Cells were then washed and resuspended in 400 l PBST containing 5 l propidium iodide and incubated at room temperature for 30 min. Samples were kept at 4°C, and analysis by flow cytometry was completed within 2 h.
Statistical analysis. All quantitative experiments were reproduced in at least three independent experiments with multiple wells in each replicate. The resulting data were expressed as means with error bars indicating means Ϯ SE. Two means were considered to be statistically significant when two-tailed Student's t-test had P Ͻ 0.05.
RESULTS
PKG2 suppresses proliferation in the colon. Loss of either guanylin or its effector GCC in IEC compromises cGMP signaling and results in increased crypt size due to expansion of the proliferative compartment (20, 44) . PKG2 is an important effector of cGMP in the intestinal mucosa, but its role in homeostasis downstream of guanylin/GCC has not been investigated. An ideal model to test this possibility is the Prkg2 Ϫ/Ϫ mouse that was created previously to demonstrate the function of PKG2 in intestinal secretion (32) . These animals were characterized in the present study to determine the role of PKG2 in intestinal homeostasis. RT-PCR and immunoblotting confirmed the absence of PKG2 expression in the colon mucosa (Fig. 1A) . Prkg2 Ϫ/Ϫ animals have a smaller stature than wild types owing to defective endochondral ossification (32) , but preliminary examination did not detect any notable macroscopic differences in the intestine. Histological examination also did not show obvious differences in the organization of the mucosa, but careful measurement revealed significantly longer crypts in the Prkg2 Ϫ/Ϫ relative to wild-type animals ( Fig. 1 , B and C). There were significantly more proliferating cells in the crypts of Prkg2 Ϫ/Ϫ animals relative to wild-type siblings as detected with either Ki-67 staining or BrdU incorporation (Fig.  1, D and E) . The relative position of the proliferating cells corresponded to the transit amplifying region, indicating that the increased crypt length is due to expansion of the progenitor cells. There are conflicting reports regarding intestinal apoptosis in GCC knockout animals relative to wild type (9, 20, 22, 43) . Significantly more apoptotic cells were observed in the proximal colon epithelium of the Prkg2 Ϫ/Ϫ animals compared with wild-type siblings when measured by either terminal deoxynucleotidyl transferase dUTP nick-end labeling or cleaved-caspase 3 immunohistochemistry (Fig. 1, F and G) .
PKG2 promotes differentiation of secretory lineage cells in the colon.
The increased crypt size and hyperplasia measured in the proximal colon of Prkg2 Ϫ/Ϫ mice has also been observed in animals deficient in guanylin (44) and its receptor GCC (20) . The GCC-deficient mice were also reported to have reduced numbers of goblet cells in the colon with no difference in enteroendocrine cells. To determine whether PKG2 influences differentiation of secretory cells, sections of proximal colons from Prkg2 Ϫ/Ϫ and wild-type animals were stained for goblet cells and enteroendocrine cells (Fig. 2A) . hypoxanthine phosphoribosyltransferase 1 (HPRT1) and ␤-actin were used as RNA and protein loading controls. B: colons were harvested from 6-wk-old WT and KO siblings, and sections were stained with hemotoxylin and eosin, the proliferation marker Ki-67, and DNA incorporation of 5-bromo-2=-deoxyuridine (BrdU). PKG2 KO mice had larger crypts (C) and an increased proliferative compartment (D and E). F: apoptotic cells in the proximal colons of WT and PKG2 KO animals were stained by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and cleaved caspase 3 (CC3). Arrows indicate cells with positive staining. Quantitation of TUNEL (G) and CC3 (H) showed significantly more apoptosis in the colon mucosa from PKG2 KO animals compared with the WT siblings. The scale bar (upper right) represents 10 m, and all panels are equal magnification. Error bars show means Ϯ SE, n ϭ 3, *P Ͻ 0.05 by two-tailed t-test.
the upper regions of the crypts than wild-type animals (approximately one-third, P Ͻ 0.001). Very similar observations were obtained independently of whether AB/PAS or Muc2 staining was used (Fig. 2, B and C) . Enteroendocrine cells represent the other secretory lineage cell that was quantitated in colon sections by staining for chromogranin A. Much like the goblet cells, there were significantly fewer enteroendocrine cells in the proximal colons of Prkg2 Ϫ/Ϫ animals relative to wild-type siblings (approximately one-half, P Ͻ 0.05). Staining for alkaline phosphatase showed no difference in colonocyte numbers between Prkg2 Ϫ/Ϫ and wild-type animals (data not shown) suggesting that PKG2 is necessary for the differentiation or maintenance of secretory cells in the colon. The effects of PKG2 status on proliferation and differentiation were most pronounced in the proximal rather than the distal colon (not shown). This regional effect in Prkg2 Ϫ/Ϫ mice is consistent with the expression of PKG2 in wild-type animals, which is higher in the small intestine but decreases along a rostrocaudal axis and is virtually undetectable in the distal colon (28) . Analysis of the ileum showed increased villus length, but more subtle changes in apoptosis and crypt hyperplasia (Fig. 3,  A-F) . Notably, Prkg2 status did not significantly affect differentiation of secretory lineage cells in the ileum (Fig. 3, G-J) .
PKG2 inhibits the proliferation of colon cancer cell lines. To better understand PKG2 signaling in the colon, its expression in colon tumors and cell lines was examined by RT-PCR and Western blot analysis. PKG2 was abundant in both normal and tumor tissue from the colon (data not shown), but was undetectable in all colon cancer cell lines examined (Fig. 4, A  and B) . This pattern of expression is reminiscent of GCC expression, which has been highlighted as a marker of metastases of intestinal origin but is absent from many colon cancer cell lines (49) . Cell lines such as T84 and Caco2 that retain GCC expression have been instrumental in characterizing downstream signaling. However, since PKG2 was not detected in any of the cell lines tested, several colon cancer cell lines were created that inducibly express PKG2 in response to Doxy. Treatment of these cell lines with Doxy resulted in robust increases in PKG2 mRNA and protein (Fig. 4, C and D) . To confirm induction of PKG2 activity, the phosphorylation of the well-characterized PKG substrate vasodilator-stimulated phosphoprotein was examined. The phosphorylation-induced electrophoretic mobility shift of vasodilator-stimulated phosphoprotein when Doxy-treated cells were stimulated with the membrane permeable analog of 8Br-cGMP, demonstrated inducible PKG2 activity.
The crypt hyperplasia observed in the colons of Prkg2 Ϫ/Ϫ mice suggested that inhibiting the proliferation of progenitor cells could be an important function of PKG2 in wild-type animals. To test this idea in vitro, colony formation assays were used to determine the effect of PKG2 expression on the proliferation of colon cancer cell lines. These studies showed that ectopic PKG2 inhibited colony formation in both LS174T (30%) and HT29 (50%) (Fig. 5, A and B) . Under identical conditions of Doxy and 8Br-cGMP, the parental cell lines that do not express PKG2 showed no significant effect (HT29) or slightly increased colony formation (LS174T). Similar effects of PKG2 on cell proliferation were obtained using MTT assays (35% decrease) and direct cell counting in a hemocytometer (25% decrease; Fig. 5, C and D) . While ectopic PKG2 reduced proliferation of viable cells, it did not significantly affect trypan blue positive cells. The ability of PKG2 to regulate cell death was further explored using annexin/propidium staining and cell cycle analysis, but neither approach was able to detect a significant effect (Fig. 5, D and E) . Notably, while the cell cycle analysis did not measure an effect of PKG2 on sub-G1 cells, there was a significant increase in G1 cells (12.5%) and a decrease in the SϩG2/M phase cells (25.6%). These results are similar to signaling downstream of GCC where cGMPdependent cytostatic effects have been reported without any effect on apoptosis.
PKG2 promotes the differentiation of colon cancer cells. The Prkg2
Ϫ/Ϫ mice had less goblet and enteroendocrine cells in the proximal colon suggesting that PKG2 might facilitate terminal differentiation in the colon mucosa. This idea has precedent as PKG2 has been reported to increase differentiation markers in glioma cell lines and in proliferating chondrocytes in the developing bone (5, 45) . To explore this possibility further, histological staining for polysaccharides and immunostaining for Muc2 was carried out as a measure of goblet cell differentiation. There was a relatively high background staining of mucopolysaccharides in the LS174T cells, but this increased significantly between 24 -48 h after PKG2 induction and activation (Fig. 6, A and B) . In contrast, there was very little background staining in HT29 cells, and this did not change when with ectopic PKG2 (data not shown). The regulation of Muc2 expression by PKG2 was examined further using RT-PCR, which showed that PKG2 activity resulted in increased Muc2 mRNA (Fig. 6, C and D) . CDX2 is a member of the Caudal homeobox genes with a critical role in the regulation of intestinal homeostasis (6) . CDX2 activity is associated with differentiating IEC and is a direct transcriptional activator of Muc2 (30, 50) . Ectopic PKG2 also increased CDX2 mRNA levels in LS174T cells with similar kinetics to Muc2. Consistent with a transcriptional regulatory mechanism, PKG2 dose dependently increased transcription from luciferase reporter constructs driven by upstream promoter regions from Muc2 (3-fold) and CDX2 (1.7-fold) genes (Fig. 6E) . In agreement with AB/PAS and Muc2 immunostaining, the increased expression of both CDX2 and Muc2 by activation of ectopic PKG2 was observed in LS174T cells but not in HT29 cells (data not shown).
A role for Sox9 downstream of PKG2. The original report of Prkg2 Ϫ/Ϫ mice described reduced GCC-mediated secretion in the intestine, but it was noted that these animals also exhibited dwarfism owing to defective endochondral ossification (32) . Subsequent work by an independent laboratory demonstrated that PKG2 blocks Sox9 repressor activity leading to hypertrophic differentiation of chondrocytes (5) . As a target of the Wnt/␤-catenin pathway, Sox9 also has an important role in intestinal homeostasis and is a transcriptional repressor of Muc2 and CDX2 genes in colon cancer cell lines (2) . Therefore inhibition of Sox9 repressor activity by PKG2 could have a role in the differentiation of LS174T colon cancer cells. Overexpression of Sox9 reduced the basal level of transcription from the Muc2-luciferase reporter in LS174T and HT29 cells (Fig. 7, A and B) . These results support the idea that partial differentiation of LS174T cells by PKG2 could result from inhibition of Sox9 repressive activity in these cells. PKG2 was reported to inhibit Sox9 in chondrocytes by blocking nuclear translocation (5), but this was not observed in the colon cancer cells examined here, where Sox9 was exclusively nuclear regardless of PKG2 status (Fig. 7C) . The nuclear localization of Sox9 was also not affected by PKG2 in glioma cells, but in that system PKG2 inhibited Sox9 expression at both protein and mRNA levels (45) . Overexpression and activation of PKG2 in LS174T cells resulted in decreased Sox9 protein, but not in HT29 cells (or in SW480 and SW620 cells; data not shown), where a slight increase in Sox9 was observed (Fig.  7D) . Additionally, while PKG2 reduced endogenous Sox9 levels, there was no effect on the level of transfected Sox9 driven by a constitutive CMV promoter. This indicated that posttranslational mechanisms were probably not responsible for the change in Sox9 protein. To explore this further, RT-PCR was used to show that expression and activation of PKG2 markedly reduced the steady-state level in LS174T but had no A: PKG2 expression in different colon cancer cell lines was examined at the RNA level by RT-PCR and compared with human colon mucosa. The Prkg2 message was not detectable in most cell lines relative to HPRT1 that was used as cDNA loading control. B: PKG2 protein was also undetectable in colon cancer cell lines measured by immunoblotting. HT29 cells transiently transfected with expression plasmids encoding human PKG2 were used as positive control, and ␤-actin was used as a loading control. C: to study PKG2 signaling, colon cancer cell lines were created that can be induced to express PKG2 by treating with doxycycline (Doxy). PKG2 expression in response to Doxy was measured by RT-PCR. D: expression of functional PKG2 protein in response to treatment with Doxy and 8Br-cGMP was assessed by mobility shift of the PKG target vasodilator-stimulated phosphoprotein (VASP). Immunoblotting to detect PKG2-phosphorylated VASP (shifted VASP-P) was done, and then blots were reprobed to detect PKG2 as indicated.
effect on Sox9 mRNA levels in HT29 cells (Fig. 7E) . The significance of Sox9 downregulation by PKG2 in vivo was investigated by immunohistological comparison of Sox9 expression in the colon mucosa of wild-type and Prkg2 Ϫ/Ϫ mice (Fig. 7, F and G) . Strong nuclear staining was observed deep in the crypts irrespective of Prkg2 status, and there was cytosolic staining in the surface epithelial cells. The cytosolic staining of Sox9 appeared to be more intense in the Prkg2 Ϫ/Ϫ mice, and there was significantly more Sox9 positive nuclei per crypt relative to wild-type siblings.
DISCUSSION
There is a significant body of evidence indicating that uroguanylin/guanylin signaling through GCC regulates intestinal homeostasis, but the downstream components remain poorly defined. Characterization of GCC and guanylin knockout mice have clearly demonstrated the importance of the cGMP signaling axis in suppressing proliferation in the intestinal epithelium (20, 22, 43, 44) . As PKG2 is a well-established downstream effector of the intestinal secretory functions of cGMP, the present study has examined Prkg2 knockout mice to determine whether this enzyme also has a role in intestinal homeostasis.
The colons of Prkg2 Ϫ/Ϫ animals exhibited an exaggerated proliferative compartment and a larger crypt size relative to Prkg2 ϩ/ϩ siblings, but there was no evidence of dysplasia or hyperplasia outside of the crypts. This effect was observed in both ileum and distal colon but was most pronounced in the proximal colon. In addition to the increased proliferation, the Prkg2 Ϫ/Ϫ animals showed significantly higher numbers of apoptotic cells and reduced numbers of secretory goblet and enteroendocrine cells. The intestinal phenotype of the Prkg2 Ϫ/Ϫ mice is remarkably similar to the GCC knockout animals (36) and strongly indicates that PKG2 mediates the homeostatic effects of GCC/cGMP in the colon. Consistent with the importance of PKG2 downstream of cGMP, both guanylin (44) and GCC (36) knockout animals also showed less pronounced homeostatic effects in the distal colon. Some controversy exists concerning GCC-dependent homeostasis in the small intestine (42) . The reduced effect of PKG2 deficiency in the distal colon likely Fig. 5 . Ectopic PKG2 inhibits the growth of colon cancer cells. Colony formation assays were used to test whether induction and activation of PKG2 (with Doxy and 8Br-cGMP) affected the growth of HT29-II16 and LS174T-II4 colon cancer cells (inducible clones). A: colonies were stained with Giemsa and imaged. B: total colony area produced by Doxy/cGMP-treated cells (ϩ) was significantly less (**P Ͻ 0.0001) than untreated controls for both cell lines. Ectopic PKG2 inhibited the proliferation (*P Ͻ 0.05) of LS174T-II4 cells as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye (MTT) assay (C) and counting cells in a hemocytometer (D). PKG2 did not affect cell death measured using trypan blue staining, where the trypan negative/ positive indicates live/dead cells, respectively. The lack of PKG2 effects on of LS174T-II4 apoptosis was confirmed by annexin/propidium staining (E) and cell cycle analysis (F). PKG2 did not affect sub-G1 cell numbers but increased G1 and reduced S/G2 cell numbers. Error bars show means Ϯ SE, *P Ͻ 0.05, two-tailed t-test, **P Ͻ 0.001 by two-tailed t-test.
reflects the expression pattern of PKG2, which decreases along a rostrocaudal axis and is virtually undetectable in the distal colon (28) . The reduced effect of PKG2 deficiency in the ileum as observed here is not explained in terms of GCC/PKG2 expression, which suggests that homeostatic signaling components downstream of PKG2 may be absent in the small intestine. It was reported recently that overlapping expression of CDX1 and CDX2 transcription factors in the proximal colon underlies differences in the regulation of epithelial homeostasis relative to the ileum and distal colon (14) . While not directly tested here, it is possible that the regulation of the differentiation-promoting CDX genes could be a central function of PKG2 in the colon and could be an important area of future investigation.
The hyperplasia in colonic crypts of PKG2 knockout animals suggests that PKG2 normally functions downstream of guanylin/GCC signaling to suppress proliferation. However, an alternative possibility is that the increased proliferation is a secondary response to the increased apoptosis and a compromised barrier (48) . A recent report demonstrating barrier dysfunction in the GCC knockout mice supports this idea (43) , but a more detailed examination of antiproliferative signaling in the PKG2 and GCC knockout animals will be necessary to fully understand the mechanism driving the hyperplasia.
The striking reduction in goblet and enteroendocrine cells in the Prkg2 Ϫ/Ϫ colons in the absence of obvious changes in the numbers of absorptive colonocytes suggests an important role for PKG2 in either secretory lineage specification or in the terminal differentiation of these cells. Reduced numbers of goblet cells has also been reported in GCC knockout mice, but that study did not observe significant changes in enteroendocrine cells (36) . This discrepancy could reflect differences in specific region of the colon examined but is more likely due to the fact that PKG2 is positioned further downstream in the cGMP signaling pathway than GCC. While mechanistic details underlying the effects of cGMP on differentiation remain to be defined, the present results indicate that PKG2 also mediates the differentiation-promoting functions of GCC signaling (36) . Goblet cells produce and secrete a protective mucus barrier that separates the epithelial surface from luminal contents, and loss of this layer results in spontaneous colitis and tumorigenesis (15, 31, 46, 47) . Muc2 Ϫ/Ϫ mice also exhibit an exasperated inflammatory response to colonocyte toxins, such as dextran sulfate sodium (DSS) (46) . The reduced numbers of mature goblet cells in the Prkg2 Ϫ/Ϫ animals suggested that they would be more sensitive to DSS insult, but no significant difference was detected compared with wild-type siblings (D. D. Browning, unpublished data). This unexpected result might be explained by the fact that DSS sensitivity is localized to the distal colon where PKG2 expression is low and the effect on goblet cells is less in the Prkg2 Ϫ/Ϫ mice. The present results are at odds with a recent report demonstrating that GCC knockout animals have reduced sensitivity to DSS (43) . The different mouse strain used in that study might account for the difference in outcome, particularly as they did not detect significant differences in goblet cells. However, reports from the same group showed that GCC activation could protect the epithelial barrier against radiation-induced damage (9) and that GCCdeficient mice have a dysfunctional intestinal barrier (10) . These ostensibly conflicting observations can be explained if a central function of GCC/cGMP is to augment the intestinal epithelial barrier either by direct survival signaling or by promoting enterocyte differentiation. This model predicts that loss of the cGMP-dependent protective mechanism in GCC knockout animals would lead to increased epithelial apoptosis and barrier dysfunction. The resistance to DSS treatment exhibited by GCC knockout animals could reflect a secondary response, such as increased proliferation, that is necessary for barrier regeneration (48) or possibly adaptation of the enteric immune system. It is clear that more work is needed to better understand the specific signaling downstream of cGMP/PKG2 in the intestinal epithelium and to separate this from secondary adaptive processes that are inherent to animal models.
Efforts to understand GCC/cGMP signaling have benefited significantly from the use of colon cancer cell lines as experimental models. As predicted by the knockout animals, GCC agonists inhibit proliferation without causing apoptosis in GCC-expressing colon cancer cells (34). Initial insight into the cytostatic mechanism highlighted the regulation of intracellular calcium levels by GCC signaling (16, 33, 35) , but more recently the inhibition of ERK and AKT has also been implicated (23, 37) . The significance of these signaling pathways in vivo and the involvement of PKG in the cytostatic effects of GCC in colon cancer cells remain important questions to be explored. Efforts to understand PKG signaling in colon cancer cells have largely focused on the type 1 isoform, while PKG2 has remained largely unexplored [reviewed recently (3, 4) ]. The expression of PKG1 is reduced in colon tumors relative to matched normal tissue and is barely detectable in colon cancer cell lines (13) . Ectopic reexpression of PKG1 in colon cancer cells blocks xenograft growth (13, 17) , presumably by inhibiting ␤-catenin/TCF (19) and hypoxia signaling (18). PKG2 expression is not reduced in colon tumors (not shown) but was not detected in any of the colon cancer cell lines examined in the present study. Ectopic reexpression of PKG2 inhibited the growth of both HT29 and LS174T cells without affecting cell death. This is reminiscent of the effects of GCC activation in colon cancer cells (34, 35) and strengthens the idea that PKG2 mediates antiproliferation signaling downstream of GCC in the colonic crypts.
In addition to the antiproliferative effects, ectopic PKG2 also increased the expression of the intestinal differentiation markers Muc2 and CDX2 in LS174T but not in HT29 colon cancer cells. The inhibition of proliferation in both colon cancer cell types but induction of differentiation only in LS174T cells suggests that these two processes are regulated by different signaling pathways. PKG2 has also been reported to promote the differentiation of glioma cells (45) and chondrocytes (5, 32) . Both systems have underscored inhibition of Sox9 repressor activity as a possible mechanism. The role of Sox9 in the gastrointestinal tract is complex, as it has a role in secretory cell lineage specification, but it is also a transcriptional repressor that blocks maturation of secretory lineage cells in the intestinal mucosa and in colon cancer lines (1, 2, 7, 26) . In agreement with previous findings (2), overexpression of Sox9 was able to reduce basal levels of Muc2 transcription in both HT29 and LS174T. However, PKG2 was only able to repress Sox9 mRNA and protein levels in LS174T cells but not in HT29. The ability of PKG2 to inhibit Sox9 function was associated with differentiation (CDX2 and Muc2 levels), which occurred in LS174T but not in HT29 cells. The mechanism by which PKG2 can reduce Sox9 levels in LS174T cells but increase Sox9 in HT29 cells is not presently known, but indicates a previously unappreciated complexity in its regulation. It is possible that PKG2 promotes secretory lineage-commitment or maturation by blocking Sox9 expression in LS174T cells, but not in the less-committed HT29 cells that do not differentiate. The mechanism underlying Sox9 downregulation by PKG2 should be the focus of future work. The increased Sox9 staining in the colon mucosa of Prkg2 Ϫ/Ϫ supports the significance of this pathway in vivo, but since Sox9 is a Wnt target gene, it is possible that the increased staining was associated with that increased numbers of proliferating cells observed in these animals. Resolution of this issue is technically challenging as Sox9 levels normally decrease as cells migrate toward the luminal surface in association with reduced ␤-catenin/TCF activity. Taken together the present work has demonstrated a novel and previously unrecognized role for PKG2 in homeostasis in the colon. The similarities between GCC and PKG2 knockout mice indicate that PKG2 is the central mediator of GCC effects on proliferation and differentiation in the colon as well as the regulation of electrolyte balance. In that regard, PKG2 might represent an additional therapeutic target for the prevention and treatment of colon malignancies.
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